Pfizer’s stock has dropped 25% from its recent high, raising questions about whether it's a buy at $23. Pipeline failures and ...

Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.

Despite Pfizer management's cost-cutting and a large drug pipeline, revenue growth remains uncertain. Click here to read an ...

PFE stock offers high dividend yields supported by cost optimizations and R&D. Discover its potential amid COVID-19 sales ...

Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely ...

We recently published a list of Jim Cramer Recently Discussed These 15 Stocks. In this article, we are going to take a look ...

Pfizer has earned a “Moderate Buy” rating from fifteen research firms, reflecting a mix of cautious optimism and mild ...

Although Pfizer has made some efforts to turn things around, they have been insufficient. Pfizer's poor performance since ...

High-yielding dividend stocks may not be the ticket to superior returns, but they can rank pretty high on the list of nice-to ...

Pfizer Inc. (NYSE: PFE) is navigating a period of strategic upheaval and legal scrutiny as it ends its clinical collaboration ...

Shares of Pfizer Inc. PFE advanced 1.16% to $23.45 Thursday, on what proved to be an all-around great trading session for the ...

Pfizer (NYSE:PFE) recently ended its strategic collaboration with Acepodia and is facing legal challenges related to ...